Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.2% – Should You Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 0.2% on Thursday . The stock traded as low as $6.20 and last traded at $6.32. 957,386 shares were traded during trading, a decline of 83% from the average session volume of 5,717,877 shares. The stock had previously closed at $6.33.

Analyst Ratings Changes

RXRX has been the topic of a number of research reports. KeyCorp dropped their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Jefferies Financial Group dropped their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Needham & Company LLC decreased their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Finally, Leerink Partners dropped their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Price Performance

The business’s 50 day simple moving average is $6.73 and its 200-day simple moving average is $7.74. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -3.90 and a beta of 0.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. During the same quarter in the prior year, the firm posted ($0.38) earnings per share. The business’s quarterly revenue was up 30.9% on a year-over-year basis. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total transaction of $76,351.49. Following the sale, the director now directly owns 7,089,007 shares in the company, valued at $47,283,676.69. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Christopher Gibson sold 30,000 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $7.10, for a total value of $213,000.00. Following the completion of the transaction, the chief executive officer now directly owns 758,738 shares in the company, valued at $5,387,039.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $6.67, for a total value of $76,351.49. Following the sale, the director now directly owns 7,089,007 shares in the company, valued at approximately $47,283,676.69. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 195,682 shares of company stock valued at $1,284,153. 15.75% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Green Alpha Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 2.9% in the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after buying an additional 1,800 shares during the period. Interchange Capital Partners LLC raised its position in Recursion Pharmaceuticals by 7.3% in the second quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock worth $268,000 after acquiring an additional 2,349 shares in the last quarter. Amalgamated Bank lifted its holdings in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $26,000. Finally, Victory Capital Management Inc. grew its stake in shares of Recursion Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after purchasing an additional 2,598 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.